Biotechnology

New patent for the Boehringer Ingelheim drug TRIJARDY XR – DrugPatentWatch

[ad_1]

Copyright © DrugPatentWatch. Originally published in New patent for the Boehringer Ingelheim drug TRIJARDY XR

Expiration of Annual Drug Patent for TRIJARDY+XR
Expiration of Annual Drug Patent for TRIJARDY+XR

Trijardy Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from a single supplier. There are fifteen patents protecting this drug.

TRIJARDY XR drug price trends.

Drug patent litigation for TRIJARDY XR.

This drug has four hundred and forty-eight patent family members in forty-eight countries.

The generic ingredients in TRIJARDY XR are empagliflozin; linagliptin; metformin hydrochloride. One registered supplier for this compound. Additional details are available on empagliflozin; linagliptin; metformin hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published in New patent for the Boehringer Ingelheim drug TRIJARDY XR

[ad_2]

Source link

Related Articles

Back to top button